From: The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
5% decline in VC at month 3
No
Yes
Total*
P-value
Subjects
194
67
261
Mean ± S.D.
0.1 ± 0.7
0.6 ± 0.9
0.2 ± 0.8
0.0002